Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Your blood cancer cells must show a certain protein called CD70 on at least 10% of the cancer cells, confirmed by a lab test before enrollment.
• You must meet additional eligibility requirements specific to your type of blood cancer (confirm with trial site).
• It must have been at least 1 week since your last chemotherapy before the preparatory treatment begins (a blood-thinning medication called Hydroxyurea is allowed closer to the start date for certain blood cancers, and some targeted therapy pills may be continued until 3 days before).
• If you have received focused radiation to one area, you may still be eligible as long as there are other areas of disease that were not radiated and can be used to track your response.
• You must be reasonably functional in daily life — measured by a performance score above a certain level (confirm with trial site).
• Your kidneys must be working well enough, shown by blood test results within acceptable ranges.
• Your liver must be working well enough, with no cirrhosis and no fluid buildup in your abdomen.
• Your heart must be pumping adequately (at least 40% efficiency), with no serious heart rhythm problems or fluid around the heart.
• Your lungs must be working well enough, with blood oxygen above 92% breathing normal air and acceptable breathing test results.
• You must be between 12 and 80 years old.
• You must weigh at least 40 kg (about 88 pounds).
• You must be willing and able to use effective birth control during the study and for 3 months after it ends, if you are able to have children.
• You must be willing to be followed up long-term as part of a separate monitoring protocol.
• You must be able to give written informed consent (either yourself or through a legally authorized representative).

Who may not be able to join:

• Women who are pregnant, breastfeeding, or who could become pregnant and test positive on a pregnancy test.
• People who still have significant side effects (Grade 3 or higher) from a previous cancer treatment.
• People who have an active infection (fungal, bacterial, viral, or other) that is not responding to treatment.
• People who have HIV with a detectable level of virus in their blood.
• People with an active neurological (brain or nerve) disorder.
• People who have had an active autoimmune disease within the past 12 months.
• People with a condition called amyloidosis or POEMS syndrome.
• People whose cancer has actively spread to the brain or the lining around the brain.
• People who currently require treatment for a complication called graft-versus-host disease (GVHD), whether acute or chronic.
• People with any other active cancer, except for certain treated skin or cervical conditions.
• People with any other serious medical condition that the doctor believes would put them at risk.
• People who have had major surgery within the past 4 weeks before starting the preparatory chemotherapy.
• People who received a donor stem cell transplant or donor white blood cell infusion within the past 12 weeks.
• People currently taking part in another experimental treatment trial.
• People currently taking other anti-cancer treatments.
• People receiving high-dose steroid therapy at the time of the cell infusion, or who have received certain immune-suppressing drugs (ATG, alemtuzumab, or similar) within a recent specified timeframe (confirm exact timeframes with trial site).
• People currently taking medications that suppress the immune system.

Important: Always verify eligibility with the trial site directly before applying.